In the latest trading session, GW Pharmaceuticals PLC closed at $166.96, marking a +1.18% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.72%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, added 0.71%.
Coming into today, shares of the company had gained 9.42% in the past month. In that same time, the Medical sector lost 0.66%, while the S&P 500 gained 0.28%.
GWPH will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$2.42, up 22.44% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $23.19 million, up 592.18% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.98 per share and revenue of $132.12 million. These totals would mark changes of +24.43% and +679.18%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GWPH. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 16.09% higher. GWPH currently has a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
GW Pharmaceuticals PLC (GWPH) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, GW Pharmaceuticals PLC closed at $166.96, marking a +1.18% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.72%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, added 0.71%.
Coming into today, shares of the company had gained 9.42% in the past month. In that same time, the Medical sector lost 0.66%, while the S&P 500 gained 0.28%.
GWPH will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$2.42, up 22.44% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $23.19 million, up 592.18% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of -$7.98 per share and revenue of $132.12 million. These totals would mark changes of +24.43% and +679.18%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GWPH. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 16.09% higher. GWPH currently has a Zacks Rank of #2 (Buy).
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 87, putting it in the top 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.